Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,570,000 shares, a growth of 5.6% from the March 15th total of 3,380,000 shares. Based on an average daily trading volume, of 717,500 shares, the short-interest ratio is currently 5.0 days.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Kezar Life Sciences in a report on Friday, March 15th.
View Our Latest Stock Analysis on Kezar Life Sciences
Institutional Investors Weigh In On Kezar Life Sciences
Kezar Life Sciences Trading Up 4.3 %
Shares of KZR stock opened at $0.82 on Thursday. Kezar Life Sciences has a 12-month low of $0.67 and a 12-month high of $3.13. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $0.89. The firm has a market cap of $59.45 million, a P/E ratio of -0.58 and a beta of 0.47.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities analysts anticipate that Kezar Life Sciences will post -1.26 EPS for the current fiscal year.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Featured Articles
- Five stocks we like better than Kezar Life Sciences
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- United Airlines Soars on Earnings Beat
- How to Use High Beta Stocks to Maximize Your Investing Profits
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Stock Dividend Cuts Happen Are You Ready?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.